Δευτέρα 3 Απριλίου 2017

AACR 2017: Avelumab was safe and yielded durable responses for patients with advanced merkel cell carcinoma

The immunotherapeutic avelumab (Bavencio) was well tolerated by patients with advanced Merkel cell carcinoma, and the majority of those whose cancer responded to avelumab treatment had durable responses, according to results from a phase II clinical trial...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nSjIkx
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις